Cardinal Health today announced plans to acquire Johnson & Johnson's Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.944 billion in cash, or approximately $1.594 billion, net of the present value of tax benefits.
Biota Pharmaceuticals has entered into a definitive agreement to acquire Anaconda Pharma, a...
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the two companies...
Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash. The companies said Sunday that their boards of directors approved the transaction, which amounts to about $158 for each of Salix's outstanding shares.
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas.
Bristol-Myers Squibb and Flexus Biosciences announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus, a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics.
Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair.
Edmond de Rothschild Investment Partners announced today that its BioDiscovery 3 portfolio company, GlycoVaxyn AG, a privately held specialist vaccine biopharmaceutical company, has been acquired by GlaxoSmithKline in an all-cash transaction valuing the company at approximately $212M.
Rite Aid and Envision Pharmaceutical Services have entered into a definitive agreement under which Rite Aid will acquire EnvisionRx, a portfolio company of leading global private investment firm TPG, in a transaction valued at approximately $2 billion, which includes the value of an expected future tax benefit of $275 million.
Actavis has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx brand acne treatment and related assets to Mayne for approximately $50M. The transaction is expected to close prior to the end of February.
The Hospira deal will add significant value to Pfizer’s GEP segment, a vertical which has been rumored to be sold or spun-off as a separate entity. This somewhat mirrors Pfizer’s strategic objective to focus on core growth platforms in the branded drug market while divesting its ancillary operations, similar to when it carved-out its Animal Health business and brought it public.
Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million.
Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its established global pharmaceutical business. The buyout will also help Pfizer tap into the growing market for biosimilars, which are cheaper versions of biologic drugs that are used to treat conditions such as anemia.
Mylan is buying some women's health care businesses from Indian health care company Famy Care Ltd. for $750 million. The deal also includes additional contingent payments of up to $50 million.
Sun Pharmaceuticals will sell the rights to one generic drug as part of its purchase of competitor Ranbaxy Laboratories, U.S. antitrust regulators said Friday. The Federal Trade Commission said the companies will sell Ranbaxy's interests in generic minocycline, an antibiotic used to treat several types of infections.
Dendreon Reaches Agreement for Valeant to Serve as “Stalking Horse Bidder” in Court-Supervised Sales ProcessJanuary 30, 2015 8:37 am | News | Comments
Under the terms of the agreement, Valeant would acquire the world-wide rights of PROVENGE® (sipuleucel-T) and certain other Dendreon assets for $296 million, subject to higher and better bids.
Mylan announced that its shareholders approved its purchase of an Abbott Laboratories business and its tax-reducing move to the Netherlands. The company also said European Union regulators cleared the deal, which Mylan values at about $5.3 billion.
Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.
SP Industries, a designer and manufacturer of laboratory equipment, biological drug manufacturing solutions, lab supplies and specialty glassware, announced today that it has acquired Stability Environments a provider of walk-in environmental rooms, glassware dryers, chambers and accessory products.
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData.
Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.
Tekmira Pharmaceuticals Corporation and OnCore Biopharma announced today that they have agreed to merge to create a global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.
This novel technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions’ growing suite of bioavailability enhancement technologies and capabilities.
Biogen Idec announced today that it has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with a portfolio of ion channel-modulating product candidates for neuropathic pain.
The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and conditions that typically command much higher price tags than conventional medications. Shire's best-selling drugs currently include the attention deficit disorder drugs Vyvanse and Adderall XR.
Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.
AmerisourceBergen and MWI Veterinary Supply, today announced that they have entered into a definitive merger agreement for AmerisourceBergen to acquire MWI Veterinary Supply (MWI), the leading animal health distribution company in the United States.
Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.
- Page 1